News archive

September 27, 2023
Reference is made to previous investor communication, i.e. September 23, 2021 and later. Lifecare is engaged with Sanofi in a Product Development Agreement aimed at advancing the miniaturization of Lifecare’s sensor technology for integration into Lifecare’s Sencell Continuous Glucose Monitoring system. Under the terms of the agreement, Sanofi has committed to provide funding contributions, supporting […]
Read more
September 26, 2023
Lifecare participated at Redeye Medtech & Diagnostics Seminar.   Lifecare presented the latest developments from the company at the Redeye Medtech & Diagnostics Seminar. The presentation was live broadcasted and can be watched at https://www.redeye.se/events/904816/redeye-theme-medtech-diagnostics-2   You also find the company presentation here: Lifecare presentation at Redeye 26th of Sept
Read more
September 22, 2023
Lifecare announce today that additional clinical data from study LFS-SEN-001 will be presented at the upcoming international diabetes conference hosted by the Diabetes Technology Society. Lifecare CSO, Professor Dr. Dr. Med. Andreas Pfützner has received an invitation to present the poster “Continuous Glucose Monitoring with an Osmotic-Pressure Based Continuous Glucose Sensor: Results of the First […]
Read more
August 23, 2023
Lifecare has shown major progress in our plan to bring the smallest Continuous Glucose Monitor (CGM) system to the market. Testing in live tissue, implementation of Quality Management System and set up of manufacturing capabilities form the three main pillars in our market-oriented development. – The results from studies concluded in 1H 2023 and the […]
Read more
July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more
June 26, 2023
Data from Lifecare’s Clinical Development Study LFC-SEN-001 was presented at the American Diabetes Association (ADA) Scientific Sessions 2023. Lifecare’s poster presentation reveals the study background, methods, and results. The results include an impressive mean average of absolute error (MARD) of 9,6%, positioning Lifecares’s Sencell technology with an accuracy that is acceptable for therapeutic (medical) decisions […]
Read more
June 20, 2023
Data from Lifecare’s Clinical Development Study LFC-SEN-001 confirm that the Company’s Continuous Glucose Monitoring (CGM) system (Sencell) has a solid clinical accuracy: the mean average of absolute error (MARD) between Sencell and matched relative reference values was 9,6%.     In context, regulatory authorities expect a MARD below 10% to acknowledge CGM for therapeutic (medical) decisions […]
Read more
May 30, 2023
Lifecare is launching a new company called Lifecare Veterinary. Now man’s best friend will also benefit from the same innovation.   – Our main focus will still be the development of the sensor for people with diabetes, increasing their quality of life. This is not, however, counterproductive to helping our pets in parallel to the […]
Read more
May 12, 2023
Finalized successful Sencell clincal study Today we can announce that we have finalized the Sencell Clinical Development Study (LFC-SEN-001) and it reveals accurate sensor performance in human subjects. – This is a very important step in the right direction to develop the next generation Continuous Glucose Monitor (CGM) for people with diabetes, says CEO Joacim Holter. […]
Read more
April 11, 2023
Today, Lifecare is pleased to announce that a sensor first used in our ongoing Clinical Development Study has confirmed an operational longevity of 12 weeks in a continued laboratory (in vitro) set up. This is yet another important milestone in the development of our Sencell technology for Continuous Glucose Monitoring (CGM).     The achievement was […]
Read more